Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti; Arielle Elkrief; Joao V. Alessi; Xinan Wang; Yvonne Li; Hersh Gupta; Daniel M. Muldoon; Arrien A. Bertram; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Adriana Barrichello; Victor R. Vaz; Malini Gandhi; Elinton Lee; Geoffrey I. Shapiro; Hyesun Park; Mizuki Nishino; James Lindsay; Kristen D. Felt; Bijaya Sharma; Andrew D. Cherniack; Scott J. Rodig; Daniel R. Gomez; Narek Shaverdian; Mehrdad Rakaee; Chaitanya Bandlamudi; Marc Ladanyi; Pasi A. Jänne; Adam J. Schoenfeld; Lynette M. Sholl; Mark M. Awad; Michael L. Cheng

doi:10.1158/1078-0432.27031210

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523cbe https://doi.org/10.1158/1078-0432.27031210

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Abstract

Ask about this paper

Discussion

Cite This Study

Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading